Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib effect on repaglinide pharmacokinetics in healthy volunteers
NCT05469113Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2019
- Primary completion
- Mar 2019
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of selpercatinib (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration of Repaglinide, Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity of Repaglinide and 7 more. Started Jan 2019; status: completed.
02
Drugs
selpercatinib
Beyond the preview
Go deeper on NCT05469113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469113.